This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, L.
Right arrow Articles by Hawkey, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, L.
Right arrow Articles by Hawkey, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2007, p. 1446-1454, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01088-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Rapid Genotyping of CTX-M Extended-Spectrum ß-Lactamases by Denaturing High-Performance Liquid Chromatography{triangledown}

Li Xu,1,2 Jason Evans,1,2 Thomas Ling,3 Kathy Nye,1 and Peter Hawkey1,2*

Health Protection Agency West Midlands Public Health Laboratory, Heart of England NHS Foundation Trust, Birmingham B9 5SS, United Kingdom,1 Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom,2 Prince of Wales Hospital, Hong Kong3

Received 29 August 2006/ Returned for modification 27 October 2006/ Accepted 21 December 2006


arrow
ABSTRACT
 
Denaturing high-performance liquid chromatography (dHPLC) is a powerful technique which has been used extensively to detect genetic variation. This is the first report of the application of dHPLC for rapid genotyping of bacterial ß-lactamase genes. The technique was specifically developed to genotype members of all blaCTX-M DNA homology groups. Thirteen well-defined blaCTX-M extended-spectrum ß-lactamase (ESBL)-producing strains were used to develop and optimize the dHPLC genotyping assay. Further evaluation was carried out with a blinded panel of 62 clinical isolates. The results of blaCTX-M genotyping achieved by dHPLC were comparable to the typing results obtained by DNA sequencing. Applying the newly developed dHPLC-based genotyping method, we successfully genotyped all 73 blaCTX-M ESBL-producing strains from the 4-month survey study. Furthermore, we found the first reported cases in the United Kingdom of clinically significant disease caused by CTX-M-14- and CTX-M-1-producing Escherichia coli strains. We conclude that the novel dHPLC assay is highly accurate, rapid, and cost-effective for the genotyping of blaCTX-M-producing ESBLs and has great potential for determining the clinical relevance of different and new blaCTX-M genotypes, as well as for epidemiological studies and surveillance programs.


arrow
INTRODUCTION
 
The emergence of extended-spectrum ß-lactamases (ESBLs) among both hospital- and community-acquired gram-negative bacteria has become a serious problem worldwide (4). The CTX-M-type ESBLs, which are non-TEM and non-SHV derivatives, represent a new and rapidly growing family of molecular class A ESBLs (4). On the basis of amino acid sequence similarities, they have been classified into five distinct phylogenetic groups: groups 1, 2, 8, 9, and 25/26. To date, more than 50 CTX-M ß-lactamases have been characterized (http://www.lahey.org). In the United Kingdom, although the first report was of a CTX-M-9-producing isolate (group 9) of Klebsiella oxytoca in Leeds in 2000 (1), the first outbreak involved CTX-M-26 (group 25/26)-producing Klebsiella pneumoniae at City Hospital, Birmingham (7). In late 2002 a sharp increase in ESBL-producing isolates of Escherichia coli from distant parts of the United Kingdom was noted, together with a major outbreak in Shropshire (3). Interestingly, a survey of fecal carriage of CTX-M-type ESBL-producing bacteria from York showed a diversity of molecular subtypes, including CTX-M-9, -14, and -15 (34). The first isolation of CTX-M-3 (group 1), CTX-M-17 and -18 (group 9), and CTX-M-8 and -40 (group 8) ß-lactamases has also recently been reported in the United Kingdom (3, 16, 35).

The diversity and increasing prevalence of CTX-M-type ESBLs presents an increasingly complex molecular epidemiological scenario in the United Kingdom (23). While CTX-M-15 has been dominant, we have noted an increasing number of the genotypes, particularly CTX-M-14 (Li Xu, unpublished observation). There is, therefore, a pressing need for high-throughput, low-cost methods for the identification of specific genotypes of CTX-M ß-lactamase genes. Various molecular methods, including multiplex PCR, have successfully been applied to the detection of all members of all five groups (36, 39). However, without full DNA sequencing, precise genotype characterization of CTX-M-type ß-lactamase genes remains a challenge. Currently, sequencing is the only method for definitive identification, but it is time-consuming and expensive.

Denaturing high-performance liquid chromatography (dHPLC) is a relatively new, powerful technique for the detection of genetic variation. The principle behind this technology has been described in detail elsewhere (38). It has successfully been used extensively for the analysis of mutations in disease-related genes (13, 20). In recent years, the technique was first developed for bacterial identification and molecular typing and has subsequently been applied to the detection of a variety of mutations in antibiotic resistance-conferring genes, such as mutations in gyrA and grlA in Staphylococcus aureus, Salmonella, Yersinia pestis, and Neisseria gonorrhoeae (10, 14, 17). The identification of mutations associated with antituberculosis drug resistance in rpoB, katG pncA, rpsL, and embB has also been reported (9, 32). The aim of our study was to establish a sensitive, rapid, and high-throughput genotyping assay for the screening of CTX-M-type ESBLs. The dHPLC genotyping method consists of three steps: separate amplification of both reference and clinical isolates of DNA by multiplex PCR, heteroduplex formation between reference and sample PCR products, and analysis of heteroduplex DNA by dHPLC. We first developed the technique with blaCTX-M-producing control strains from the four groups and then evaluated the assay with a blinded panel of 62 previously characterized clinical isolates (39). Finally, the dHPLC assay was applied to explore the prevalence of diverse CTX-M-type ESBLs in our hospital in a 4-month survey carried out from September to December 2005 in Heartlands Hospital, Birmingham, United Kingdom.


arrow
MATERIALS AND METHODS
 
Bacterial strains and antimicrobial susceptibility testing. Thirteen well-defined blaCTX-M-producing strains were used as controls to develop and optimize the dHPLC genotyping assay (Table 1). To evaluate the accuracy of the optimized assay, a collection of 62 blaCTX-M-positive isolates from our previous study (39), including 43 from group 1 (40 CTX-M-15 isolates and 3 CTX-M-3 isolates), 16 belonging to group 9 (10 CTX-M-14 isolates and 6 CTX-M-9 isolates), and 3 CTX-M-26 producers were tested in the preliminary stage. To test the field applicability of the dHPLC method, 78 ESBL-producing consecutive nonduplicate clinical isolates from both community- and hospital-based patients were collected during the period from September to December 2005. Community-acquired isolates were from patients who had not been hospitalized in the preceding 3 months, residents of nursing homes, and outpatients; hospitalized patients with a first positive culture obtained after 48 h of hospital admission were considered to have nosocomial infections. These isolates included 58 E. coli isolates, 15 Klebsiella spp., and 5 Enterobacter cloacae isolates.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Control strains used to evaluate the dHPLC genotyping assay

All isolates were first tested for their susceptibility to cefpodoxime by the British Society for Antimicrobial Chemotherapy disk diffusion method (http://www.bsac.org.uk). ESBL production was confirmed phenotypically by using cefpodoxime, ceftazidime, and cefipirome with and without clavulanic acid.

Multiplex PCR detection of blaCTX-M genes. All isolates were initially screened for the presence of blaCTX-M by our previously described mutiplex PCR protocol (39), except that Optimase proofreading DNA polymerase (Transgenomic Inc., Omaha, NE) was used. Four sets of primers were used to amplify fragments of blaCTX-M open reading frames of CTX-M-type ESBLs, which are designed to give product sizes of 341 bp (group 2), 293 bp (group 9), 255 bp (group 1), and 207 bp (groups 25/26 and 8).

Heteroduplex formation and dHPLC analysis. Representative control strains (confirmed by DNA sequencing) GZ3 (CTX-M-3), Y19 (CTX-M-9), J1 (Toho-1), and ESBL530 (CTX-M-25) were used as reference standards for groups 1, 9, 2, and 25/26, respectively. PCR products (5 µl) of either the control or the clinical isolates were mixed with an equal amount of DNA amplified from a reference standard to ensure that consistent peak heights (absorbance, minimum of 2 mV) were observed between different runs. The mixtures were heated to 95°C for 5 min and then gradually cooled to 25°C at a rate of 1°C/min to form homo- and heteroduplex DNA molecules.

Aliquots of 5 to 8 µl of each duplexed PCR product were loaded onto a DNAsep column in a WAVE 4500 DNA fragment analysis system (Transgenomic Inc.). The linear dHPLC acetonitrile gradient consisted of buffer A (0.1 M triethylamine acetate) and buffer B (0.1 M triethylamine acetate, 25% acetonitrile). The injected DNA was eluted at a flow rate of 1.5 ml/min for 3.3 min with a specific concentration of buffer B and was detected by measurement of the absorbance at 260 nm.

The gradient conditions and the heteroduplex analysis temperature required to obtain a successful resolution of the heteroduplex were predicted with Navigator software (Transgenomic, Inc.) and the dHPLC Melt Program developed at Stanford University (http://insertion.stanford.edu/melt.html) by using the reference amplicon sequences. The results were shown in the form of chromatographic peaks. The chromatographic peaks for controls, the blind test evaluation panel, and the unknown blaCTX-M type were compared with each other by visual inspection and with the reference homoduplex peak, which was obtained by reannealing of an equal amount of reference PCR products.

DNA sequence analysis. The dHPLC genotyping results were further confirmed by DNA sequencing of a limited number of isolates (10 of 78) from the 4-month survey study. PCR fragments covering the whole open reading frame of the relevant blaCTX-M gene were cleaned by using a QIAquick PCR purification kit (QIAGEN). One hundred nanograms of the PCR product was used as the template for TaqCycle sequencing with an ABI Prism BigDye Terminator (version 3.0) cycle sequencing kit. The cycle sequencing products were analyzed on an ABI PRISM 3700 DNA analyzer (Functional Genomics Laboratory, University of Birmingham).


arrow
RESULTS
 
Development and optimization of the dHPLC genotyping assay. The sequences of the PCR amplicons of 13 control strains from four blaCTX-M groups (groups 1, 2, 9, and 25/26) were aligned and analyzed. The sequence diversity within the PCR fragments of the control strains for each group is summarized in Table 2. When the 15 sequence variations within the PCR fragments from four blaCTX-M groups were analyzed, it was found that 8 led to a change in the amino acid sequence and that 7 were silent mutations.


View this table:
[in this window]
[in a new window]

  		TABLE 2. DNA sequence variations among PCR amplicons of blaCTX-M groups generated by multiplex PCR

To determine whether dHPLC can be used as a rapid method of screening or identifying CTX-M-type ESBLs within a group, we first selected as the reference strain one strain from each group and formed a homoduplex and a heteroduplex with the PCR amplicons representing the different members of blaCTX-M genes from the relevant group. Then a qualitative comparison of the dHPLC elution profiles between the control and the reference strains was made. A total of 13 control strains (including 1 reference strain for each group), 5 from group 1, 3 from group 9, 3 from group 2, and 2 from group 25/26, were used to develop and optimize the dHPLC genotyping assay. The detection of sequence variation by dHPLC relies on a comparison of the chromatogram elution patterns between the sample (containing heteroduplex molecules) and the reference (containing homoduplex molecules). The initial temperatures for successful resolution of homo- and heteroduplex molecules were obtained by the simulation of the melting behavior of the reference sequence by using both Navigator software (Transgenomic Inc.) and the dHPLC Melt Program developed at Stanford University. The predicted temperatures of the entire strands of the blaCTX-M PCR fragments for distinguishing the molecules by use of the Navigator software/the dHPLC Melt Program were 63.5°C/62°C, 63.8°C/63.3°C, 63.1°C/62°C, and 64.6°C/62.8°C for groups 1, 9, 2, and 25/26, respectively.

To obtain the optimal temperature for the detection of single nucleotide or multiple sequence variations between reference blaCTX-M strains and other representative control strains within the group, all samples were initially analyzed at a wider range of temperatures up to ±3°C of the predicted highest and lowest temperatures in order to achieve the best resolution of heteroduplexes. The reference strains analyzed in the four groups produced a single peak at all temperatures tested (i.e., a true homoduplex). The dHPLC patterns of PCR amplicons containing sequence variations showed significant deviations from the corresponding elution profile of the reference amplicon. Alterations in the dHPLC chromatogram profile were observed at different temperatures. As the analysis temperature increases, the peak reduces in height and broadens in width. An example of a single nucleotide substitution (AGG to AGC), which resulted in an Arg-to-Ser 275 change between blaCTX-M-Toho-1 (the reference strain) and blaCTX-M-2 within group 2, is shown in Fig. 1. In contrast to the samples containing the blaCTX-M-Toho-1 reference sequence, which shows a single peak of a homoduplex DNA profile at all temperatures tested (Fig. 1A), Fig. 1B depicts the blaCTX-M-2 dHPLC signatures (three or two peaks) when the melting temperature was raised from 62°C to 63 and 65°C. Although the predicted temperatures were 63.1°C/62°C, the highest detection efficiency for blaCTX-M-2 was observed to be 64°C.


Figure 1
View larger version (8K):
[in this window]
[in a new window]

  		FIG. 1. Effect of column temperature on sequence variation detection by dHPLC. dHPLC profiles. (A) blaCTX-M-Toho-1 (the homoduplexed reference strain) with a single peak observed at all temperatures between 62°C and 65°C; (B) heteroduplexed blaCTX-M-2. The single nucleotide substitution (AGG to AGC) was detected at both 64°C and 65°C as three and two peak profiles, respectively.

The temperature window at which sequence variations of the blaCTX-M amplicons within a group can be identified was ascertained (Table 3). The optimal temperatures for obtaining dHPLC typing signatures ranged from a single temperature of 65°C for blaCTX-M-32 to six temperatures ranging from 60 to 65°C for blaCTX-M-5. Figure 2 presents the dHPLC chromatograms at these optimal temperatures for all control strains of the four blaCTX-M groups investigated in this study. For the blaCTX-M group 1 amplicons analyzed, blaCTX-M-12 and blaCTX-M-15 contained single base substitutions; blaCTX-M-1 and blaCTX-M-32 harbored two and three mismatches (Table 2) from the sequence of the blaCTX-M-3 reference strain. Although the optimal temperature of 64°C alone is sufficient for obtaining a distinct dHPLC profile for each blaCTX-M genotype, the dHPLC signature for blaCTX-M-32 was resolved into clearer double peaks at 65°C (Fig. 2A). To achieve 100% sensitivity and 100% specificity, it would be necessary to analyze amplicons at two temperatures (64°C and 65°C) for group 1 isolates. The single optimal temperature of 64°C for distinguishing blaCTX-M member strains for groups 2 and 25/26 was achieved (Fig. 2B and D, respectively). However, for group 9, although a single temperature was attained for differentiation, the higher temperature of 67°C, which is 3°C higher than the predicted temperature, was required (Fig. 2C).


View this table:
[in this window]
[in a new window]

  		TABLE 3. Temperature titration used to identify optimum temperature at which clear dHPLC chromatograms are seen


Figure 2
View larger version (23K):
[in this window]
[in a new window]

  		FIG. 2. dHPLC genotyping of blaCTX-M genes at different column temperatures. The single optimal temperature for differentiation of blaCTX-M variants within each group is boxed. The single peak profile of the reference strain (marked with an asterisk) for each group is shown only at the optimal temperature. (A) Genotyping of group 1 blaCTX-M genes; (B) genotyping of group 2 blaCTX-M genes; (C) genotyping of group 9 blaCTX-M genes; (D) genotyping of group 25/26 blaCTX-M genes.

blaCTX-M PCR amplicons from group 1 were analyzed under the same temperature conditions in three separate runs, and dHPLC produced highly reproducible chromatograms (data not shown).

dHPLC evaluation with clinical isolates. A total of 62 clinical isolates carrying sequences confirmed to be known blaCTX-M genes from a previous study (39) were subjected to blinded dHPLC analysis in order to assess the reproducibility and the sensitivity of the dHPLC genotyping method. The collection included clinical isolates from groups 1, 9, and 25/26. No group 2 clinical isolates were available to us. Our dHPLC assay correctly genotyped all 62 isolates, with 53 showing characteristic chromatogram profiles that were different from the profile for the reference strain of each group and from each other. All isolates carrying the same blaCTX-M gene had indistinguishable profiles (results not shown). For the remaining nine isolates, dHPLC typing showed single peak profiles corresponding to those for the reference strains: six isolates with profiles corresponding to blaCTX-M-9 and three isolates with profiles corresponding to blaCTX-M-3. The overall dHPLC typing results were 100% compatible with the data obtained by sequencing in our previous study (39).

Molecular typing of blaCTX-M genes from the 4-month survey by dHPLC analysis. During the 4-month period from September to December 2005, a total of 2,562 nonduplicate isolates of the family Enterobacteriaceae were processed in the clinical diagnostic service in the Birmingham Public Health Laboratory, Heartlands Hospital. A total of 78 ESBL producers were identified (3%), including 52 of 1,236 (4.1%) strains from hospitals and 26 of 1,326 (2%) strains from the community. The majority of the 78 clinical isolates were associated with urinary tract infections (66 [84%] strains); but they were also isolated from 6 sputum samples (7.8%), 3 cases of bacteremia, 2 wound infections, and 1 ascitic fluid sample. Multiplex PCR screening for the presence of blaCTX-M genes yielded amplicons of the expected size from 73 of 78 isolates. The five blaCTX-M PCR-negative isolates were further screened by a blaSHV PCR, and three isolates were positive. The remaining two isolates may have possessed ESBLs other than CTX-M and SHV. Of the 73 blaCTX-M-producing isolates, 71 belonged to blaCTX-M group 1 and 2 were found to harbor group 9 blaCTX-M genes. By using blaCTX-M-3 as the reference strain, the dHPLC genotyping of group 1 isolates at the two column temperatures of 64°C and 65°C revealed that 70 (95.8%) had blaCTX-M-15-specific elution profiles at 65°C and that 1 had the blaCTX-M-1-specific three-peak pattern at both 64°C and 65°C. The two group 9 isolates depicted a blaCTX-M-14-specific chromatogram signature when their patterns were compared with that of the blaCTX-M-9 control (results not shown). The clinical sites, the distribution of species, and the CTX-M genotypes are summarized in Table 4. All 70 blaCTX-M-15-producing isolates yielded identical profiles, and Fig. 3 demonstrates the signature matching between the CTX-M-15 control and the clinical isolates from the 4-month survey producing the blaCTX-M-15 gene. Seven of 70 (10%) that typed as CTX-M-15 ß-lactamase producers by dHPLC, as well as isolates which possessed blaCTX-M-1 and blaCTX-M-14, were sequenced. The genotypes predicted by dHPLC were verified by the sequencing results (sequences with GenBank accession no. DQ915953, DQ915954, and DQ915955).


View this table:
[in this window]
[in a new window]

  		TABLE 4. Bacterial species, specimen type, and distribution of blaCTX-M and blaSHV genotypes among 78 ESBL clinical isolates


Figure 3
View larger version (17K):
[in this window]
[in a new window]

  		FIG. 3. Overlay of dHPLC signatures to assess reproducibility of characteristic features of CTX-M-15. The top chromatogram is the CTX-M-15 control signature and is compared to signatures from two blaCTX-M-15-producing clinical isolates from the survey.


arrow
DISCUSSION
 
The dHPLC technology for mutation detection has facilitated the more efficient analysis of sequence variations and has led to a better understanding of the role that such variations play in the development of diseases such as cancer (21). It is also regarded as one of the most specific and sensitive techniques for mutation detection, with a specificity and a sensitivity approaching 100% each (38). To date, the dHPLC technique has seen limited applications to both bacterial species identification and the detection of mutational changes within antibiotic resistance-associated genes. However, its potential usefulness for rapid screening of the genotypes of antibiotic resistance-associated variants has been little explored (10, 14). In this study, the use of dHPLC for the rapid screening of blaCTX-M gene variants has been investigated.

The dHPLC technology is typically used to detect point mutations in DNA sequences by comparing the chromatograms of a wild-type (reference) strain and an experimental sample. Phylogenetic analysis of the target gene (blaCTX-M) has allowed the definition of five distinct groups which show very limited cross-group sequence homology. In addition, within each of these groups as many as 20 mutational changes have been seen between two members. The lack of sequence homology between different phylogenetic groups also precludes identification of a single PCR target that will facilitate cross-group discrimination. To accommodate these features of blaCTX-M variation, we have developed a multiplex PCR-based approach (39).

The principle of the dHPLC typing strategy applied in this study is illustrated for group 1 blaCTX-M isolates in Fig. 4. When dHPLC is applied to the genotyping of highly variable genes, such as blaCTX-M, the choice of the reference strain is crucial. For the typing of group 1 isolates, GZ3 carrying blaCTX-M-3 was selected as the reference strain because in the United Kingdom blaCTX-M-15-producing isolates account for greater than 95% of all CTX-M-type ESBLs from both community and hospital patients. The blaCTX-M-15 gene contains a single nucleotide substitution (A725 to G725) compared to the sequence of blaCTX-M-3, which leads to the Asp-240-Gly change (by the numbering system of Ambler et al. [2]). This mutation has been shown to increase hydrolytic activity against ceftazidime (5) and can be readily discriminated from blaCTX-M-3 by dHPLC (Fig. 2A). It is worth mentioning that three other group 1 strains, CTX-M-28, -29, and -33, also differ from CTX-M-3 by a single nucleotide (A750 to G750) within the PCR amplicon. However, these three strains are rare variants. CTX-M-33 and CTX-M-29 have been reported in only one E. coli strain each in Greece and China, respectively (40). Since the first report of its isolation in France, CTX-M-28 has appeared in only one Chinese hospital. Given the fact that CTX-M-15 is the predominant group 1 genotype in the United Kingdom, the chromatogram obtained by dHPLC very likely predicts the presence of blaCTX-M-15. Therefore, we believe that our dHPLC typing technique is robust enough to serve as a rapid screening genotyping method; and in an outbreak of CTX-M-type ESBL infection, sequencing of a proportion of the isolates should be undertaken in order to confirm the blaCTX-M genotypes of the outbreak strains (Fig. 4). In addition to allowing the sensitive identification of the blaCTX-M-15 genotype, Fig. 2A also shows the high sequence-specific discriminatory power of the dHPLC technique, in which other subtypes of group1 blaCTX-M variants can be distinguished from those of the reference strain and each other on the basis of their chromatogram profiles.


Figure 4
View larger version (28K):
[in this window]
[in a new window]

  		FIG. 4. Algorithm for dHPLC genotyping of blaCTX-M-producing ESBLs in a clinical laboratory.

As described above, one of the key factors influencing the efficiency of detection of sequence variation by dHPLC is the column temperature used. The correlation of our experimentally determined optima with those predicted by the two computer programs used showed that the Navigator program gave a closer correlation than the dHPLC Melt Program did, but neither of the programs was able to predict the temperature at which the maximum discrimination was achieved for all four of the blaCTX-M group amplicons being analyzed. This limitation in the predictive value of these algorithms is possibly due to the fact that for each amplicon, multiple sequence variations at different positions in the amplicon must be differentiated. This perhaps is more demanding for the software, because some variants can be identified at several temperatures while others are resolved at only a single temperature. Previous reports (18) have shown that a 2°C increase above the predicted discriminatory optimum was necessary to maximize mutation detection. However, in this study we found that 67°C, which is 3°C higher than the predicted optimum, was required in order to achieve the best discrimination of the group 9 blaCTX-M-producing strains evaluated. Of the PCR amplicons tested for the four groups, the single temperature was sufficient to differentiate the member strains of three groups and only the group 1 amplicon required analysis at two temperatures in order to achieve maximum specificity. In addition to the column temperature, the G+C content of the DNA analyzed, the numbers and types of mutations within the DNA fragment, and the DNA concentration all affect the efficiency of mutation detection in terms of the shapes, numbers, and heights of heteroduplex peaks. In this study DNA concentrations are standardized before analysis, but some minor variation (one of the factors causing differences in the heights of each of the peaks) may inevitably occur. Signature matching between control isolates (with known mutations) and clinical isolates (Fig. 3) is the most important key to the identification of mutations and to the interpretation of changes in the shapes or the heights of the peaks.

The blinded validation with 62 clinical blaCTX-M producers from our previous study showed that dHPLC genotyping was able to assign all of the strains to the correct genotype.

The method described in this paper detects sequence variations in 200- to 300-bp fragments of the blaCTX-M gene, which enables the differentiation of isolates into distinct CTX-M genotypes. The current "gold standard" for precise genotyping and the identification of novel enzymes is complete DNA sequencing of the entire 0.87-kb blaCTX-M gene. To further improve the specificity of dHPLC typing technique and to enable the detection of all novel enzymes by dHPLC, two potential approaches are currently under investigation. First, a dHPLC typing assay with a whole-gene PCR amplicon could be developed; although DNA fragments of up to 1.5 kb have been used for dHPLC-based mutation detection (27), the high level of sequence diversity within the blaCTX-M gene may complicate chromatogram interpretation. Second, and alternatively, two PCR amplicons that cover the entire CTX-M gene could be used and the simultaneous appearance of characteristic peak profiles in two fragments may provide a specific genotype fingerprint.

Since the early 1990s, the rapid expansion of the CTX-M type of ESBLs has created great concern in the public health community worldwide. The prevalence of different CTX-M types of ESBL varies geographically. While the predominant genotypes have been CTX-M-14 and -9 in Spain (15, 31), CTX-M-14 and -3 in China (40), CTX-M-1 in Italy (8), and CTX-M-2 in both Japan and Argentina (30, 33), CTX-M-15 is the most prevalent genotype in the United Kingdom, with an epidemic CTX-M-15-producing strain (strain A) being identified (37).

Our 4-month survey is the first comprehensive prospective study of the genotyping of all isolates with a blaCTX-M-producing ESBL in a large group of teaching hospitals (1,100 beds) in the United Kingdom. Applying the newly developed dHPLC-based genotyping method, we successfully genotyped all 73 blaCTX-M ESBL-producing strains in our sample set. Our data have confirmed the findings of the general screening of isolates referred to the United Kingdom Health Protection Agency's Antibiotic Resistance Monitoring and Reference Laboratory from 42 centers during 2003, that is, that CTX-M-15 is the predominant type of CTX-M ß-lactamase in the United Kingdom (37). The 4-month survey showed that 57/58 (98%) ESBL-producing E. coli strains harbored the blaCTX-M gene (Table 4). This much higher rate of detection of CTX-M-type ESBLs in clinically significant E. coli isolates may suggest that blaCTX-M has been exceptionally successful in both community and hospital settings in the south Birmingham area. Since its first description in 2001 (19), CTX-M-15 has rapidly spread worldwide, including to Asia, Europe, South America, Africa, and the Middle East (11, 12, 24, 26, 29, 34). More alarmingly, CTX-M-15- producing E. coli strains have recently caused reported outbreaks in countries such as Italy, where previously only CTX-M-1 ß-lactamases have been reported (25), and in France and Spain, where the clonal dissemination of CTX-M-15 in hospitals had previously never been reported (22, 28). The availability of high-throughout genotyping by our dHPLC technique will enable the spread of blaCTX-M-15 as well as all the other major outbreak genotypes of CTX-M (blaCTX-M-1, blaCTX-M-2, blaCTX-M-3, blaCTX-M-9, blaCTX-M-12, blaCTX-M-13, blaCTX-M-14, and blaCTX-M-26) to be monitored. The dHPLC genotyping results from our survey have demonstrated the discriminatory power of our technique, as we have found the first reported cases of clinically significant disease caused by CTX-M-14- and CTX-M-1-producing E. coli strains in the United Kingdom. Since TEM-type ESBLs have rarely been encountered in clinical isolates in the United Kingdom, blaTEM was not screened for in this study.

This is the first report demonstrating the application of the dHPLC technology to the genotyping of ß-lactamases and was particularly applied to CTX-M-type ESBLs. The technique has many advantages. It is reliable, and the PCR products are processed in a 96-well autosampler unit and continuously injected onto the column for analysis without any time-consuming premanipulations, such as purification and denaturation. Other major advantages over sequencing are the high-throughput capability (with 3.3 min/injection, 100 samples can be analyzed in 6 h) and low consumables cost (at least 10 times less than the cost of consumables for sequencing). It can be applied to clinical isolates on a large scale inexpensively, and it can also be used to determine the clinical relevance of different genotypes and can be applied in epidemiological studies and surveillance programs. By using dHPLC, the worldwide distribution of blaCTX-M genotypes and their subsequent evolution can be delineated, and furthermore, any novel mutations/insertions/deletions can potentially be detected as a new chromatograph profile.


arrow
ACKNOWLEDGMENTS
 
We are grateful to Guillaume Arlet (Hôpital Tenon, Paris, France), Michael Mulvey (National Microbiology Laboratory, Manitoba, Canada), German Bou (Complejo Hospitalario Universitario Juan Canalejo, Spain), Sam Kariuki (Kenya Medical Research Institute, Nairobi, Kenya), Leonidas Tzouvelekis (Hellenic Pasteur Institute, Athens, Greece), Yoshikazu Ishii (School of Medicine, Toho University, Tokyo, Japan), and Jianhui Xiong (representing the Guangzhou Antimicrobial Resistance Surveillance Group, China) for supplying the control strains.

We thank Anthony Jones, the Functional Genomics Laboratory, University of Birmingham (BBSRC grant 6/JIF 13209), for DNA sequencing and all individuals at Transgenomic, Crewe, United Kingdom, for technical support.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Health Protection Agency, West Midlands Public Health Laboratory, Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, United Kingdom. Phone: 44 (0) 121 424 1240. Fax: 44 (0) 121 7726229. E-mail: peter.hawkey{at}heartofengland.nhs.uk Back

{triangledown} Published ahead of print on 8 January 2007. Back


arrow
REFERENCES
 
    1
  1. Alobwede, I., F. H. M'Zali, D. M. Livermore, J. Heritage, N. Todd, and P. M. Hawkey. 2003. CTX-M extended-spectrum beta-lactamase arrives in the UK. J. Antimicrob. Chemother. 51:470-471.[Free Full Text]
    2. 2
  2. Ambler, R. P., A. F. Coulson, J. M. Frere, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276:269-270.
    3. 3
  3. Batchelor, M., K. Hopkins, E. J. Threlfall, F. A. Clifton-Hadley, A. D. Stallwood, R. H. Davies, and E. Liebana. 2005. blaCTX-M genes in clinical Salmonella isolates recovered from humans in England and Wales from 1992 to 2003. Antimicrob. Agents Chemother. 49:1319-1322.[Abstract/Free Full Text]
    4. 4
  4. Bonnet, R. 2004. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1-14.[Free Full Text]
    5. 5
  5. Bonnet, R., C. Recule, R. Baraduc, C. Chanal, D. Sirot, C. de Champs, and J. Sirot. 2003. Effect of D240G substitution in a novel ESBL CTX-M-27. J. Antimicrob. Chemother. 52:29-35.[Medline]
    6. 6
  6. Bradford, P. A., Y. Yang, D. Sahm, I. Grope, D. Gardovska, and G. Storch. 1998. CTX-M-5, a novel cefotaxime-hydrolyzing beta-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimicrob. Agents Chemother. 42:1980-1984.[Abstract/Free Full Text]
    7. 7
  7. Brenwald, N. P., G. Jevons, J. M. Andrews, J. H. Xiong, P. M. Hawkey, and R. Wise. 2003. An outbreak of a CTX-M-type beta-lactamase-producing Klebsiella pneumoniae: the importance of using cefpodoxime to detect extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 51:195-196.[Free Full Text]
    8. 8
  8. Brigante, G., F. Luzzaro, M. Perilli, G. Lombardi, A. Coli, G. M. Rossolini, G. Amicosante, and A. Toniolo. 2005. Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int. J. Antimicrob. Agents 25:157-162.[CrossRef][Medline]
    9. 9
  9. Cooksey, R. C., G. P. Morlock, B. P. Holloway, J. Limor, and M. Hepburn. 2002. Temperature-mediated heteroduplex analysis performed by using denaturing high-performance liquid chromatography to identify sequence polymorphisms in Mycobacterium tuberculosis complex organisms. J. Clin. Microbiol. 40:1610-1616.[Abstract/Free Full Text]
    10. 10
  10. Eaves, D. J., E. Liebana, M. J. Woodward, and L. J. Piddock. 2002. Detection of gyrA mutations in quinolone-resistant Salmonella enterica by denaturing high-performance liquid chromatography. J. Clin. Microbiol. 40:4121-4125.[Abstract/Free Full Text]
    11. 11
  11. Edelstein, M., M. Pimkin, I. Palagin, I. Edelstein, and L. Stratchounski. 2003. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob. Agents Chemother. 47:3724-3732.[Abstract/Free Full Text]
    12. 12
  12. Gangoue-Pieboji, J., V. Miriagou, S. Vourli, E. Tzelepi, P. Ngassam, and L. S. Tzouvelekis. 2005. Emergence of CTX-M-15-producing enterobacteria in Cameroon and characterization of a blaCTX-M-15-carrying element. Antimicrob. Agents Chemother. 49:441-443.[Abstract/Free Full Text]
    13. 13
  13. Hall, A. G., P. Hamilton, L. Minto, and S. A. Coulthard. 2001. The use of denaturing high-pressure liquid chromatography for the detection of mutations in thiopurine methyltransferase. J. Biochem. Biophys. Methods 47:65-71.[CrossRef][Medline]
    14. 14
  14. Hannachi-M'Zali, F., J. E. Ambler, C. F. Taylor, and P. M. Hawkey. 2002. Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC). J. Antimicrob. Chemother. 50:649-655.[Abstract/Free Full Text]
    15. 15
  15. Hernandez, J. R., L. Martinez-Martinez, R. Canton, T. M. Coque, and A. Pascual. 2005. Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain. Antimicrob. Agents Chemother. 49:2122-2125.[Abstract/Free Full Text]
    16. 16
  16. Hopkins, K. L., A. Deheer-Graham, E. J. Threlfall, M. J. Batchelor, and E. Liebana. 2006. Novel plasmid-mediated CTX-M-8 subgroup extended-spectrum beta-lactamase (CTX-M-40) isolated in the UK. Int. J. Antimicrob. Agents 27:572-575.[CrossRef][Medline]
    17. 17
  17. Hurtle, W., L. Lindler, W. Fan, D. Shoemaker, E. Henchal, and D. Norwood. 2003. Detection and identification of ciprofloxacin-resistant Yersinia pestis by denaturing high-performance liquid chromatography. J. Clin. Microbiol. 41:3273-3283.[Abstract/Free Full Text]
    18. 18
  18. Jones, A. C., J. Austin, N. Hansen, B. Hoogendoorn, P. J. Oefner, J. P. Cheadle, and M. C. O'Donovan. 1999. Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin. Chem. 45:1133-1140.[Abstract/Free Full Text]
    19. 19
  19. Karim, A., L. Poirel, S. Nagarajan, and P. Nordmann. 2001. Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol. Lett. 201:237-241.[Medline]
    20. 20
  20. Klein, B., G. Weirich, and H. Brauch. 2001. DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations. Hum. Genet. 108:376-384.[CrossRef][Medline]
    21. 21
  21. Kleymenova, E., and C. L. Walker. 2001. Determination of loss of heterozygosity in frozen and paraffin embedded tumors by denaturating high-performance liquid chromatography (DHPLC). J. Biochem. Biophys. Methods 47:83-90.[CrossRef][Medline]
    22. 22
  22. Lavollay, M., K. Mamlouk, T. Frank, A. Akpabie, B. Burghoffer, S. Ben Redjeb, R. Bercion, V. Gautier, and G. Arlet. 2006. Clonal dissemination of a CTX-M-15 beta-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob. Agents Chemother. 50:2433-2438.[Abstract/Free Full Text]
    23. 23
  23. Livermore, D. M., and P. M. Hawkey. 2005. CTX-M: changing the face of ESBLs in the UK. J. Antimicrob. Chemother. 56:451-454.[Abstract/Free Full Text]
    24. 24
  24. Moubareck, C., F. Doucet-Populaire, M. Hamze, Z. Daoud, and F. X. Weill. 2005. First extended-spectrum-beta-lactamase (CTX-M-15)-producing Salmonella enterica serotype Typhimurium isolate identified in Lebanon. Antimicrob. Agents Chemother. 49:864-865.[Free Full Text]
    25. 25
  25. Mugnaioli, C., F. Luzzaro, F. De Luca, G. Brigante, M. Perilli, G. Amicosante, S. Stefani, A. Toniolo, and G. M. Rossolini. 2006. CTX-M-type extended-spectrum ß-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob. Agents Chemother. 50:2700-2706.[Abstract/Free Full Text]
    26. 26
  26. Neuwirth, C., E. Siebor, M. Pruneaux, M. Zarnayova, C. Simonin, J. P. Kisterman, and R. Labia. 2003. First isolation of CTX-M15-producing Escherichia coli from two French patients. J. Antimicrob. Chemother. 51:471-473.[Free Full Text]
    27. 27
  27. Nickerson, M. L., G. Weirich, B. Zbar, and L. S. Schmidt. 2000. Signature-based analysis of MET proto-oncogene mutations using DHPLC. Hum. Mutat. 16:68-76.[CrossRef][Medline]
    28. 28
  28. Oteo, J., C. Navarro, E. Cercenado, A. Delgado-Iribarren, I. Wilhelmi, B. Orden, C. Garcia, S. Miguelanez, M. Perez-Vazquez, S. Garcia-Cobos, B. Aracil, V. Bautista, and J. Campos. 2006. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J. Clin. Microbiol. 44:2359-2366.[Abstract/Free Full Text]
    29. 29
  29. Pagani, L., E. Dell'Amico, R. Migliavacca, M. M. D'Andrea, E. Giacobone, G. Amicosante, E. Romero, and G. M. Rossolini. 2003. Multiple CTX-M-type extended-spectrum beta-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J. Clin. Microbiol. 41:4264-4269.[Abstract/Free Full Text]
    30. 30
  30. Quinteros, M., M. Radice, N. Gardella, M. M. Rodriguez, N. Costa, D. Korbenfeld, E. Couto, and G. Gutkind. 2003. Extended-spectrum beta-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob. Agents Chemother. 47:2864-2867.[Abstract/Free Full Text]
    31. 31
  31. Romero, L., L. Lopez, L. Martinez-Martinez, B. Guerra, J. R. Hernandez, and A. Pascual. 2004. Characterization of the first CTX-M-14-producing Salmonella enterica serotype Enteritidis isolate. J. Antimicrob. Chemother. 53:1113-1114.[Free Full Text]
    32. 32
  32. Shi, R., K. Otomo, H. Yamada, T. Tatsumi, and I. Sugawara. 2006. Temperature-mediated heteroduplex analysis for the detection of drug-resistant gene mutations in clinical isolates of Mycobacterium tuberculosis by denaturing HPLC, SURVEYOR nuclease. Microbes Infect. 8:128-135.[CrossRef][Medline]
    33. 33
  33. Shibata, N., H. Kurokawa, Y. Doi, T. Yagi, K. Yamane, J. Wachino, S. Suzuki, K. Kimura, S. Ishikawa, H. Kato, Y. Ozawa, K. Shibayama, K. Kai, T. Konda, and Y. Arakawa. 2006. PCR classification of CTX-M-type beta-lactamase genes identified in clinically isolated gram-negative bacilli in Japan. Antimicrob. Agents Chemother. 50:791-795.[Abstract/Free Full Text]
    34. 34
  34. Valenzuela de Silva, E. M., A. Mantilla, Jr., M. T. Reguero Reza, E. B. Gonzalez Mejia, M. Pulido, I. L. Dario, I., and D. Velandia. 2006. Detection of CTX-M-1, CTX-M-15, and CTX-M-2 in clinical isolates of Enterobacteriaceae in Bogota, Colombia. J. Clin. Microbiol. 44:1919-1920.[Free Full Text]
    35. 35
  35. Winstanley, T. G., E. J. Ridgway, B. T. Parys, N. Woodford, E. Ward, and D. M. Livermore. 2004. First isolation of a CTX-M-3 beta-lactamase producer in the United Kingdom. Int. J. Antimicrob. Agents 24:625-627.[CrossRef][Medline]
    36. 36
  36. Woodford, N., E. J. Fagan, and M. J. Ellington. 2006. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum ß-lactamases. J. Antimicrob. Chemother. 57:154-155.[Free Full Text]
    37. 37
  37. Woodford, N., M. E. Ward, M. E. Kaufmann, J. Turton, E. J. Fagan, D. James, A. P. Johnson, R. Pike, M. Warner, T. Cheasty, A. Pearson, S. Harry, J. B. Leach, A. Loughrey, J. A. Lowes, R. E. Warren, and D. M. Livermore. 2004. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J. Antimicrob. Chemother. 54:735-743.[Abstract/Free Full Text]
    38. 38
  38. Xiao, W., and P. J. Oefner. 2001. Denaturing high-performance liquid chromatography: a review. Hum. Mutat. 17:439-474.[CrossRef][Medline]
    39. 39
  39. Xu, L., V. Ensor, S. Gossain, K. Nye, and P. Hawkey. 2005. Rapid and simple detection of blaCTX-M genes by multiplex PCR assay. J. Med. Microbiol. 54:1183-1187.[Abstract/Free Full Text]
    40. 40
  40. Yu, Y., S. Ji, Y. Chen, W. Zhou, Z. Wei, L. Li, and Y. Ma. 2007. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China. J. Infect. 54:53-57.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, April 2007, p. 1446-1454, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01088-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Evans, J. T., Parveen, A., Smith, G. E., Xu, L., Chan, E. W. C., Chan, R. C. Y., Hawkey, P. M. (2009). Application of denaturing HPLC to rapidly identify rifampicin-resistant Mycobacterium tuberculosis in low- and high-prevalence areas. J Antimicrob Chemother 63: 295-301 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, L.
Right arrow Articles by Hawkey, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, L.
Right arrow Articles by Hawkey, P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»